Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Addresses HCV Vulnerability With Strong Genotype 3 Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead is looking at second-generation two- and three-drug combinations to stem the weaknesses of Harvoni, particularly in genotype 3, but Merck and AbbVie also are focusing on this large subgroup of HCV. Meanwhile, Bristol is working to bolster its indication in genotype 3.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register